Valk Lab

Comprehensive analyses of acute myeloid leukemia (AML) using genomics to better understand AML biology and improve AML patient outcomes

Peter (P.J.M.) Valk

E-mail: p.valk@erasmusmc.nl

Scopus: link

PubMed: link

Contact:

Leenke de Jong-de Visser, secretary, m.dejong-devisser@erasmusmc.nl

Dr Peter J.M. Valk received his PhD degree in 1999 at the Department of Hematology at Erasmus University Rotterdam, on the identification of novel leukemia oncogenes using retroviral mutagenesis (with Prof Dr B. Löwenberg).  He worked as a research fellow awarded by the Dutch Cancer Society in the Department of Hemato-oncology  at the Children’s Hospital in Boston (with Prof Stuart Orkin). In 2000, Dr Valk returned to the Department of Hematology at the Erasmus University Medical Center as Associate Professor and Head of the Hemato-oncology Laboratory (cytology and molecular diagnostics – reference laboratory in HOVON-AMLSG-NCRI clinical trials).


Our research

The department of Hematology at Erasmus MC is involved in clinical and translational research aimed at the improvement of treatment and diagnosis of hematological malignancies. The department coordinates and participates in multicenter clinical trials (HOVON/SAKK) and has a major focus on the delineation of the biology of hematologic malignancies and the development of molecular diagnostics for these diseases. The aim of these programs is to dissect the cellular and molecular pathogenesis of these conditions and translate them to clinical practice.

Dr Valk’s main interest is unraveling the molecular heterogeneity of hematologic malignancies, in particular acute myeloid leukemia (AML). Using various genome-wide technologies, such as gene expression profiling, genotyping and next generation sequencing, Dr Valk revealed novel insights into the heterogeneity and biology of AML. His work has developed molecular biomarkers that are incorporated into routine risk-stratification and clinical care of AML patients. More recently Dr Valk has focused on the detection of molecular minimal residual disease In AML, clonal hematopoiesis and germline predisposition to myeloid malignancy.


Our team

Peter Valk, principal investigator

Jeanine Gastreich, research technician

Francois Kavelaars, research technician

Melissa Rijken, research technician

Jolinda Konijnenburg, research associate

Lisanne Beugelink, PhD student

Thijs van Bergen, PhD student

Emma Boertjes, PhD student

Alumni

Roxanne Cromwell

Tim Grob

Christian Vonk


Key publications

Hourigan CS, Beugelink L, Othman J, Gui G, Ivey A, Dillon RJ, Thiede C, Levis MJ, Dillon LW, Wei AH, Tiong IS, Loo S, Döhner K, Arnhardt I, Kowalik A, Potter N, Kim DDH, Preudhomme C, Duployez N, Heuser M, Peter ValkELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia. Blood. 2026 Jun 3:blood.2026033569. doi: 10.1182/blood.2026033569. 

 

de Cássia Cavaglieri R, Nardinelli L, Rijken M, Gouveia-Lima AS, Peter Valk, Traina F, Rego EM.SOHO State of the Art Updates and Next Questions | Implementing Next-Generation Sequencing (NGS) in Resource-Constrained Settings: The Experience of the International Consortium on Acute Leukemias (ICAL). Clin Lymphoma Myeloma Leuk. 2026 Jun;26(6):351-356.e1. doi: 10.1016/j.clml.2026.03.008. Epub 2026 Mar 18.PMID: 42031658 

 

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

Boertjes EL, Grob T, Al Hinai A, Beverloo BHB, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska PL, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Löwenberg B, Peter Valk. MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities. Blood Adv. 2026 Feb 24;10(4):939-950. doi: 10.1182/bloodadvances.2025018408.PMID: 41529224

 

Cloos J, Peter Valk, Thiede C, Döhner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bücklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026 Mar 12;147(11):1147-1167. doi: 10.1182/blood.2025031480.PMID: 41397238

 

Boertjes EL, Vonk CM, Kavelaars FG, Engvall M, Nordin S, Beugelink L, Rijken M, Konijnenburg JML, Versluis J, Löwenberg B, Peter Valk. Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. Blood Adv. 2025 Oct 14;9(19):4860-4869. doi: 10.1182/bloodadvances.2025016726.PMID: 40674738

 

Vonk CM, Grob T, Rijken M, Kavelaars FG, Konijnenburg JML, Ossenkoppele GJ, Manz MG, Havelange V, Fløisand Y, Löwenberg B, Peter Valk. Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML. Blood Adv. 2025 Mar 11;9(5):1069-1077. doi: 10.1182/bloodadvances.2024014490.PMID: 3963730

 

Vonk CM, Boertjes EL, Kavelaars FG, Rijken M, Konijnenburg JML, Cromwell RE, Löwenberg B, Grob T, Peter Valk. Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA. Hemasphere. 2024 Aug 15;8(8):e141. doi: 10.1002/hem3.141. eCollection 2024 Aug.PMID: 39148661